An Extension Study of ABT-806 for Subjects With Advanced Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety (Number of subjects with adverse events)
Evaluation of vitals signs, clinical lab testing and adverse event monitoring (every other week), physical exam (every 4 weeks) and ECG (at final visit)
At each treatment visit (every other week throughout the study or up to 51 weeks)
Yes
Kyle D. Holen, MD
Study Director
AbbVie
United States: Food and Drug Administration
M12-326
NCT01406119
October 2011
December 2013
Name | Location |
---|---|
Site Reference ID/Investigator# 58882 | Boston, Massachusetts 02215 |
Site Reference ID/Investigator# 58883 | Baltimore, Maryland 21231 |